MIAMI, Sep 20, 2021 (GLOBE NEWSWIRE) – Cryo-Cell International, Inc. (Nasdaq: CCEL), the leader in cryopreservation of blood and cord tissue, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi on the Board of Directors of the Company, replacing Mr. George Gaines and Jonathan Wheeler, MD, who have resigned as directors. Mr. Gaines chose to retire while Dr. Wheeler resigned for health reasons.

The Board of Directors voted unanimously in favor of adding Mr. Mark Portnoy and Mr. Daniel Mizrahi as members of the Board. Mr. Portnoy is the co-CEO of the company and was previously a member of the board of directors from 2011 to 2020. Mr. Mizrahi is currently President and CEO of Power Tech, SA Power Tech is a leading manufacturer and distributor in Guatemala of over 2,500 items, including medical products, women’s personal care products and hardware tools in over 3,000 retail stores.

The Company would like to thank Mr. Gaines and Dr. Wheeler for over ten years of valuable and dedicated service as Directors of the Company and wish them both the best in their future endeavors.

“It has been gratifying and gratifying to be a part of the transformation of Cryo-Cell over the past ten years.

“It has truly been an honor to serve on the Cryo-Cell Board of Directors for the past ten years. This year marked a significant transition for the company, due to the licensing agreement with Duke University and the recent listing on NASDAQ. The progress made and the opportunities ahead represent the hard work of our leadership as well as the important role Cryo-Cell maintains in the cord blood and tissue industry, ”said Dr. Wheeler.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents in 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and stem cells from cord tissue. In addition to its private banking, Cryo-Cell International has a public banking program in partnership with Duke University. The Cryo-Cell Public Bank has provided cord blood for more than 600 transplants and operates cord blood donation sites across the United States at leading hospitals such as Cedars-Sinai Hospital in Los Angeles. and the Baptist Hospital in Miami. The Cryo-Cell installation is FDA registered, cGMP / cGTP compliant, and licensed in all licensing states. In addition to being accredited by the AABB as a cord blood establishment, Cryo-Cell was also the first cord blood bank in the United States (for private use only) to receive FACT accreditation for joining. to the highest cord blood quality standards set by any independent and internationally recognized accreditation organization. . Cryo-Cell owns the exclusive rights to PrepaCyte-CB, the most advanced cord blood processing technology in the industry.

Cryo-Cell’s mission has been to provide customers with state-of-the-art cord blood and cord tissue cryopreservation services, educate expectant parents about the possibility of banking or donating their baby’s cord blood and support the advancement of regenerative medicine. In February 2021, Cryo-Cell entered into a licensing agreement with Duke University that transformed Cryo-Cell into a stand-alone, vertically integrated cell therapy company capable of treating patients.

For more information, please visit IR.cryo-cell.com

Forward-looking statement

Statements herein, the terms “believes”, “intends”, “plans”, “anticipates”, “expects”, and similar expressions used are intended to reflect “forward-looking statements” of the Society. The information contained in this document is subject to various risks, uncertainties and other factors which could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are beyond the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion and product diversification initiatives, participation real future of the Company in future therapies resulting from its collaborative research partnerships. , the success related to its intellectual property portfolio, the future competitive position of the Company in stem cell innovation, the future success of its core business and the competitive impact of public cord blood banks on the businesses of the Company, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of the profitability of its biopharmaceutical manufacturing and operating clinics , the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of these initiatives and collaborations, the success and applicability of the Umbilical Cord Blood License Agreements and umbilical tissue of the company, as well as the associated intellectual property and their ability to provide the Company with royalties, and the risks and uncertainties contained in the risk factors described in documents which the Company files from time to time with the Securities and Exchange Commission, including the most recent annual report on form 10-K, quarterly reports on form 10 -Q and all current reports on Form 8-K filed by the company. The Company disclaims any obligation to subsequently revise forward-looking statements to reflect events or circumstances occurring after the date of such statements.

For more information please contact:
Corporate Communication / Investor Relations
Diane Glanz, Rph, PharmD.
Telephone: +1 (813) 749-2195
Email: [email protected]


Source link

Leave a Reply

Your email address will not be published.